Bristol Myers Squibb was among the investors in a series B round announced alongside a collaboration with the small molecule drug developer.
US-based small molecule therapeutics developer Octant Bio has secured $80m in a series B round that included Bristol Myers Squibb (BMS), the pharmaceutical firm with which it recently struck a partnership.
Life sciences investment firm Catalio Capital Management led the round, which also featured boutique investment bank Allen & Company and venture capital firms 50 Years VC and Andreessen Horowitz, the latter through its Bio Fund.
Octant has developed a drug development technology platform which combines synthetic chemistry and computation…
